TREACE MEDICAL CONCEPTS, INC. — Form 8-K
Filed August 7, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Treace reported Q2 2026 revenue of $45.4M (down 4% from $47.4M in Q2 2025) and net loss of $(15.9)M or $(0.24)/share. The company raised full-year 2026 revenue guidance to $204M–$212M (previously $202M–$212M) and improved Adjusted EBITDA guidance to a loss of $(3.0)M–$(5.0)M (previously $(4.0)M–$(6.0)M). Cash position stands at $45.6M; year-to-date cash usage reduced 57% versus 2025. Case volumes accelerated YoY; 40% of Lapiplasty surgeons adopted one or more of three new bunion systems launched in Q3 2025.
Why this rating
Modest revenue decline offset by cost control and improved guidance. Cash runway adequate at $45.6M (17% of market cap). Portfolio expansion and case growth are positive signals but losses persist. Moderate business development.
See more from August 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.